Health
Ozempic, Weight-Loss Drugs Probed Over Reports of Suicidal Thoughts
- Regulator investigating Ozempic, Saxenda after reports flagged
- Other weight-management drugs linked to such side effects: FDA
This article is for subscribers only.
Novo Nordisk A/S’s weight-loss medications are under investigation by the European Union’s drugs regulator after a small number of reports of suicidal risks were referred to the watchdog.
The European Medicines Agency is looking at adverse events noted by the Icelandic Medicines Agency, including two cases of suicidal thoughts linked to the drugs Saxenda and Ozempic, the EMA said in a statement Monday. One additional case relating to thoughts of self-injury has been raised in connection with Saxenda. The EMA did not report any cases of suicide, and suicidal behavior is not currently listed as a side effect in the EU product information of the drugs.